Aclarion, Inc. (ACON) Stock Analysis & Investment Frameworks
Aclarion, Inc. (ACON) stock analysis on Invetso. Review Aclarion, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aclarion, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Healthcare Information Services
- Country: US
Aclarion, Inc. Key Financial Metrics
- Market Cap: $1.40M
- Revenue: $75730.00
- ROE: -59.34%
- ROIC: -57.11%
- Dividend Yield: N/A
About Aclarion, Inc.
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Aclarion, Inc. Investment Frameworks
Invetso analyzes Aclarion, Inc. (ACON) across the following frameworks:
- Aclarion, Inc. 10Y Growth Potential
- Aclarion, Inc. Scenario Analysis
- Aclarion, Inc. Risks & Opportunities
- Aclarion, Inc. Economic Moat
- Aclarion, Inc. Business Model
- Aclarion, Inc. Management
- Aclarion, Inc. SWOT Analysis
- Aclarion, Inc. Porter's 5 Forces
- Aclarion, Inc. PESTLE Analysis
- Aclarion, Inc. ESG Analysis